How to Value a Cannabis Dispensary in 2026

Cannabis dispensary valuation has gone through a full cycle in five years. In 2021, single-location dispensaries in limited-license states were trading at 8-12x EBITDA and MSOs were paying premiums on top of that. By 2024, I was closing deals at 3x, and some operators in saturated markets couldn't find buyers at any price. In 2026, the market has stabilized but at dramatically lower multiples — and the gap between scarce-license markets and open markets has widened to the point where they're barely the same industry.

If you're running a dispensary and thinking about an exit, the two questions that matter more than any other are: how scarce is your license, and are you vertically integrated? Everything else is secondary. Here's how cannabis retail valuation actually works in 2026.

The Range: 2-5x EBITDA, Plus License Value

Cannabis dispensaries in 2026 generally trade in a 2-5x EBITDArange for the operating business, with a separate license premium layered on top in limited-license states. The range is wider than almost any other retail vertical I work in because the variables — state law, license scarcity, vertical integration, location, and 280E exposure — all move independently.

Where you land depends primarily on buyer type:

• Individual operator buying a single store: 2-3x EBITDA. Limited capital, strict SBA ineligibility, mostly seller financing.
• In-state consolidator (3-10 stores): 3-4x EBITDA. Strategic synergies on purchasing and compliance, willing to pay a modest premium for fit.
• MSO strategic acquisition: 4-6x EBITDA plus license premium. Public or PE-backed, buying for market entry or footprint expansion.
• License-driven deal in a capped state: Sometimes irrelevant — the buyer is paying for the license and the dispensary is essentially a wrapper.

License Premium: The Headline Number

In limited-license states, the license itself carries most of the enterprise value. I've closed deals where a dispensary doing $6M in revenue with barely-breakeven EBITDA sold for $18M because the license was one of twelve in a metro area with 2 million people. I've also seen $8M-revenue dispensaries in Denver trade for under $2M because the market had 500+ competing licenses.

Rough 2026 license premiums I'm seeing in the market:

• Florida (medical, vertically integrated): $15M-$40M per license, driven by extreme scarcity and pending adult-use.
• New York (retail): $3M-$10M, highly variable by location and compliance posture.
• New Jersey: $4M-$12M for adult-use retail in prime locations.
• Massachusetts: $2M-$6M, declining as the market saturates.
• Illinois (craft/social equity): $1M-$3M, with significant restrictions on transferability.
• California, Oregon, Colorado, Michigan, Washington: Effectively zero. License is a commodity.

Named buyers active in dispensary M&A in 2026 include Curaleaf, Green Thumb Industries, Trulieve, Cresco Labs, Verano, and increasingly regional consolidators like Ayr Wellness, Jushi Holdings, and Schwazze. Each has distinct state priorities and will pay meaningfully different numbers for the same dispensary based on strategic fit.

Vertical Integration: The Multiple Booster

A dispensary operating as pure retail — buying product from third-party wholesalers — trades at the low end of the range. A vertically integrated operator with cultivation, processing, and retail under one roof trades at the high end, often with a 1-2x multiple premium.

There are three reasons. First, margins are structurally higher because the operator captures the wholesale margin on house brands. Second, 280E hits less painfully because cost of goods sold is effectively internal transfer and more of the tax base ends up as deductible COGS. Third, strategic buyers pay up for vertical integration because it accelerates their own playbook and reduces supply chain risk.

The gotcha: vertical integration only works if each leg of the business is operationally strong. A dispensary attached to a poorly-run cultivation operation is worse than a standalone dispensary because the buyer inherits a money-losing grow that can't easily be wound down. I've seen multi-state operators walk away from otherwise attractive dispensary deals specifically because the cultivation component was underperforming.

Unit Economics: The Retail Benchmarks

When I'm valuing a dispensary, I benchmark against a set of operating metrics that tell me whether the business is healthy independent of market conditions:

• Revenue per square foot: $1,500-$3,000 is standard. Above $4,000 suggests a destination location or strong limited-license market.
• Average ticket: $55-$85 adult-use, $80-$120 medical. Declining average ticket is a warning sign.
• Basket size: 2.5-3.5 items per transaction. Good loyalty programs push this higher.
• Gross margin: 40-50% for retail-only, 55-65% for vertically integrated.
• Labor as percent of revenue: 12-18%. Above 20% is a red flag.
• Return customer rate: 55-70%. The best operators have loyalty app data that proves it.

Buyers will ask for twelve months of POS data and reconcile it to Metrc and tax filings. Dispensaries with clean, reconciled data trade at a measurable premium to those where the numbers don't tie out.

280E and True Cash Flow

Dispensaries get hit even harder than cultivators by Section 280E because retail operations can't deduct most of their operating expenses for federal tax purposes. A dispensary reporting $2M in EBITDA often has $800K-$1.2M in after-federal-tax cash flow. When sophisticated buyers model a deal, they apply the multiple to the after-tax number, not the reported EBITDA. If your broker is pitching you a valuation based on reported EBITDA, you're going to be disappointed in diligence.

When normalizing EBITDA for a cannabis dispensary, I adjust for:

• 280E tax burden: Calculate the real federal bill and deduct it above the line.
• Related-party real estate: Normalize rent if the owner leases from themselves.
• Owner compensation: Replace with a $90K-$140K general manager salary.
• One-time compliance spend: Legal fees for license acquisition or defense should be pulled out.
• Shrinkage and theft: Normalize to 1-2% of revenue. Higher than that indicates control weakness and buyers discount for it.

What Kills Dispensary Value

Local tax rates. Some California cities impose 15%+ local cannabis taxes on top of state excise, which crushes margins. A dispensary in Oakland faces a fundamentally different economic reality than one in Las Vegas.

Compliance violations. Pesticide failures, Metrc discrepancies, sales to minors — any of these in the 24 months before sale can reduce license transferability and shave 20-40% off enterprise value.

Cash management issues. Because banking is limited, many dispensaries run on cash. Poor cash controls, missing deposit records, and weak POS reconciliation all signal due diligence risk.

Lease problems. Cannabis leases often include cannabis-specific termination clauses, rent escalators, and landlord approval requirements for change of control. A lease with under 3 years remaining and no extension is a material problem.

Single-location dependency. A sole-location operator with all revenue tied to one store, one parking lot, and one local political environment gets valued more cautiously than a small chain.

How to Maximize Your Exit

Clean up Metrc and POS data. Twelve months of reconciled data is the minimum to be taken seriously. Eighteen to twenty-four months is better.

Document compliance history. Gather every inspection report, correction notice, and renewal document. Buyers will ask, and volunteering clean records earns credibility.

Negotiate lease extensions. Before going to market, extend your lease to at least 5 years with clear change-of-control language.

Build a house brand. Dispensaries with a house flower or edible brand that drives 15%+ of revenue trade at a premium because margin and stickiness are higher.

Match buyer type to your story. If you're in a scarce-license state with a weak operating business, target MSOs who want the license. If you're in a saturated market with strong operations, target in-state consolidators who value operational excellence.

The Bottom Line

Cannabis dispensary valuation in 2026 is a tale of two industries. In scarce-license states, you're selling a regulatory asset that happens to come with a retail store, and the multiples reflect license value more than operations. In saturated markets, you're selling a 280E-burdened retail business with compressed margins and tough unit economics, and multiples are honest but modest. Knowing which market you're in — and structuring your sale process around the right buyer pool for that market — is the single biggest decision you'll make in the entire exit.